$EQ

Connelly Stephen sold $91K of EQ

Connelly Stephen (President and CSO) sold 30,975 shares of Equillium, Inc. (EQ) at $2.94 on 2026-06-05.

Original reporting
SEC EDGAR · Connelly Stephen
Published Jun 5, 2026, 8:42 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EQ
Neutral
medium confidence
Mentioned
$EQ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EQNeutralLow
01

Why it matters

The disclosed sale can influence short-term sentiment, but it does not provide new operational, clinical, or financial information.

02

Market read

Traders may monitor for follow-on insider activity or correlate with upcoming company events, but the filing alone is not a standalone catalyst.

03

What to watch

The article lacks context on prior insider transactions, total holdings change over time, and whether the sale was part of any non-10b5-1 arrangement—these can materially change interpretation.

Relevance 6/10Novelty 6/10Timing: Filed today (2026-06-05), after-hours SEC disclosure

Background

SEC Form 4 reports insider transactions; this filing is an open-market sale by Equillium’s President & CSO.

Company-level read

Ticker impact

$EQNeutralMedium confidence
Context

Equillium insider Stephen Connelly (President & CSO) filed an open-market sale of 30,975 shares at $2.9401 on 2026-06-05.

Expected impact

Low, likely sentiment-only; any impact should be limited unless follow-on selling or new fundamentals emerge.

Evidence & confidence

Insider sales on Form 4 are common and often occur under routine liquidity plans; this filing specifies no 10b5-1 plan, but the article provides no additional context (e.g., size vs. history, earnings linkage).

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/product update.

None.

None.

Counterpoint

Without a 10b5-1 plan, the sale could still be unrelated to fundamentals (tax/liquidity/portfolio rebalancing), so bearish read-through may be overstated.

Key entities

  • Equillium, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Stephen Connelly

    President and CSO who sold 30,975 shares on 2026-06-05.

Related articles

$EQMedAI 8/10

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium (NASDAQ:EQ) presented preclinical data linking aryl hydrocarbon receptor (AhR) activation to miR-124 induction, led by CSO Stephen Connelly. Using its AhR modulator EQ504 and Abivax’s obefazimod (ABX464), the company reported miR-124 induction in immune cells with AhR antagonism reducing it, alongside decreases in pro-inflammatory cytokines. ABX464 showed an AhR EC50 ~400 nM in reporter assays. Equillium said Phase 1 readouts will focus on colon tissue drug exposure (EC50–EC90) and CYP